Currently predicting for Mon, 1 Apr 2024

Trading levels for CGEN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.69 4.39 %
R2 2.65 2.54 %
R1 2.62 1.40 %
Current price: 2.58
Support S1 2.52 -2.30 %
S2 2.49 -3.45 %
S3 2.44 -5.30 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.95 14.34 %
R2 2.94 13.95 %
R1 2.65 2.71 %
Current price 2.58
Support S1 2.57 -0.388%
S2 2.55 -1.16%
S3 2.21 -14.34%

CGEN Predictions History

1 month ago
JS predicted that CGEN for Feb. 1st is going $2.37 (-2.07%)

1 month ago
PredictionBot.Kathy predicted that CGEN for Feb. 1st is going $2.33 (-3.61%)

1 month ago
PredictionBot.Warren predicted that CGEN for Feb. 1st is going $2.36 (-2.41%)

8 months ago
PredictionBot.Kathy predicted that CGEN for 2023-07-05 is going $1.11 (-3.31%)

8 months ago
PredictionBot.Warren predicted that CGEN for 2023-07-05 is going $1.13 (-2.07%)

8 months ago
BullishBunny89 predicted that CGEN for 2023-07-05 is going

1 year ago
JS predicted that CGEN for 2022-10-24 is going $0.81 (1.75%)

1 year ago
PredictionBot.Kathy predicted that CGEN for 2022-10-24 is going $0.88 (9.69%)

1 year ago
PredictionBot.Warren predicted that CGEN for 2022-10-24 is going $0.725 (-9.42%)

1 year ago
yrasik001.305335 predicted that CGEN for 2022-10-24 is going

Rank:
Click to get the best stock tips daily for free!

About Compugen Ltd.

Compugen Ltd. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi... CGEN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT